Roche Holding AG has high hopes for the investigational COVID-19 antibody cocktail from Regeneron Pharmaceuticals, Inc. it is helping to develop but Bill Anderson, head of pharma at the Swiss major, has warned that even if REGN-COV2 gets approval, demand will far outstrip supply.
REGN-COV2, a combination of two antibodies (REGN10933 and REGN10987) has been much in the news since doctors administered the treatment...







